June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization
Author Affiliations & Notes
  • Joao J Nassaralla
    Retina and Vitreous, Instituto de Olhos de Goiania and UnB, Goiania, Brazil
  • Arthur A Nassaralla
    Medicina, Faculdade de Medicina São Leopoldo Mandic, Campinas, São Paulo, Brazil
  • Miguel Hage Amaro
    Retina e Vítreo, Instituto de Olhos e Laser de Belém, Belem, PA, Brazil
  • João Jorge Nassaralla
    Faculdade de Medicina , UFG, Goiânia, Goiás, Brazil
  • Footnotes
    Commercial Relationships   Joao Nassaralla, None; Arthur Nassaralla, None; Miguel Amaro, None; João Jorge Nassaralla, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 262. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joao J Nassaralla, Arthur A Nassaralla, Miguel Hage Amaro, João Jorge Nassaralla; Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2017;58(8):262.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To evaluate the clinical results of EYLEA® (aflibercept) intravitreal injection (RII) in choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV).

Methods : 20 patients with subfoveal PM-CNV, were treated with of 2 mg ( 50microliters) RII. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed. RII were repeated only in case of persistent angiographic leakage and if OCT scans showed retinal thickening or edema and serous retinal detachment. The follow-up period was at least 3 years.

Results : The mean age of the study patients was 28 years (21-37) and the mean refractive error -11.25 D. At 36 months post-treatment, mean VA increased from 20/100 (20/400 -20/40) to 20/50 (20/200-20/30). Only 3 patients lost 35 letters due to macular atrophy; the other 7 increased or stabilized their VA. Mean macular thickness decreased from 352 to 230 µm. No ocular or general side effects were recorded.

Conclusions : These short-term results suggest that RII are effective and safe in patients with PM-CNV. The number of patients in this pilot study was limited and the follow-up is too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.